سعر جارديانس 25 مجم 30 قرص 2024

Empagliflozin 25 mg film-coated tablets, an oral SGLT2 inhibitor used in type 2 diabetes, heart failure and chronic kidney disease.

• To reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure.Population: AdultsDailyMed (U.S. National Library of Medicine)
• To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death and hospitalisation in adults with chronic kidney disease at risk of progression.Population: AdultsDailyMed (U.S. National Library of Medicine)
• To reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (5% or more) in adults with type 2 diabetes: urinary tract infections and female genital mycotic infections.International label, same product · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to empagliflozin or any excipient (reactions such as angioedema have occurred).International label, same product · DailyMed (U.S. National Library of Medicine)

• Ketoacidosis: markedly increased risk in type 1 diabetes (not indicated); ketoacidosis can also occur in type 2 diabetes and with pancreatic disorders.International label, same product · DailyMed (U.S. National Library of Medicine)
• Volume depletion with symptomatic hypotension or acute kidney injury; higher risk with eGFR below 60, in the elderly and with loop diuretics.International label, same product · DailyMed (U.S. National Library of Medicine)
• Genitourinary infections including urosepsis, pyelonephritis, genital mycotic infections and necrotising fasciitis of the perineum (Fournier's gangrene).International label, same product · DailyMed (U.S. National Library of Medicine)

• DiureticsIncreased urine volume and frequency may enhance volume depletion; assess volume status and renal function before starting and monitor.DailyMed (U.S. National Library of Medicine)
• Insulin and insulin secretagoguesIncreased risk of hypoglycaemia; a lower dose of insulin or the secretagogue may be required.DailyMed (U.S. National Library of Medicine)

• Not recommended during the second and third trimesters based on adverse renal effects in animals; limited human data are insufficient to determine a risk of major birth defects or miscarriage.International label, same product · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended while taking empagliflozin because of a possible risk to the developing infant kidney; empagliflozin is present in rat milk.International label, same product · DailyMed (U.S. National Library of Medicine)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing reabsorption of filtered glucose and lowering the renal threshold for glucose, which increases urinary glucose excretion; also reduces sodium reabsorption.